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Abstract
Background: Breast cancer is currently the most common neoplasm diagnosed in women globally. There is a growing
body of evidence to suggest that human papillomavirus (HPV) infection may play a key role in invasiveness of breast
cancer. The aim of this study was to determine the presence of HPV in patients with breast cancer and its possible
association with cancer progression.
Methods: Breast specimens were collected from 72 patients with breast cancer and 31 healthy controls. The presence
of HPV was investigated by polymerase chain reaction (PCR) and genotyping was performed for positive cases. We also
evaluated the viral factors such as E6, E2, and E7 in HPV positive cases. Enzyme-linked immunosorbent assay (ELISA (and
Real-time PCR techniques were used to measure the expression level of anti-carcinogenic genes, such as p53,
retinoblastoma (RB), breast and ovarian cancer susceptibility gene (BRCA1, BRCA2) and inflammatory cytokines, including
tumor necrosis factor α (TNF-α), transforming growth factor β (TGF-β), nuclear factor-kB (NF-kB), and different
interleukins [ILs] (IL-1,IL6, and IL-17).
Results: The HPV DNA was detected in 48.6% of breast cancer samples, whereas only 16.1% of controls were positive
for HPV. We observed statistically significant differences between breast cancer patients and HPV presence (P = 0.003).
HPV type 18 was the most prevalent virus genotype in patients. The expression of P53, RB, BRCA1, and BRCA2 were
decreased in patients with HPV-positive breast cancer as compared to HPV-negative breast cancer and healthy controls.
(All P-values were less than 0.05). The presence of the HPV was associated with increased inflammatory cytokines (IL-1,
IL-6, IL-17, TGF-β, TNF-α, and NF-kB) and tumor progression.
Conclusion: The present study demonstrated that HPV infection may implicate in the development of some types of
breast cancer.
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Background
Breast cancer is one of the most common cause of can-
cer deaths among women in both developing and devel-
oped countries. Moreover, mortality of this cancer is
much more than both colorectal and lung cancers [1–3].
In the past two decades, the breast cancer rate has been
increased worldwide with a considerable pace which has
been suggested to be due to increasing known and/or
unknown risk factors (RFs) of this cancer. A group of these
RFs could be infectious agents which play a key role as
carcinogens or promoters [4–6]. Recent studies have iden-
tified that some viruses, especially human papilloma virus
(HPV), are among the RFs for the development of breast
cancer, suggesting a strong association between HPV and
breast cancer [7–10]. Many researches have been done on
association between human papilloma virus (HPV) and
cervical cancer and this issue is well accepted that HPV
has the strong causal link with this cancer [9, 10]. For the
first time in 1992, the association between breast cancer
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and HPV was reported by Lonardo et al. [11]. The HPV is
a non-enveloped DNA virus which belongs to the Papillo-
maviridae family with over 150 types [12]. It has been
shown that at least a few types of HPV such as 6, 11, 15,
16, 18, and 33 are related to breast cancer [13, 14]. The
genome of such viruses are divided into three main seg-
ments; long control region (LCR), early region (E) which
encoding E1, E2, E4–E7, and late region (L) consisting of
L1 and L2 [15]. E6 and E7 proteins, the oncoproteins,
mainly act as stimulators of host cell proliferation [16]. E6
protein is a greatly important functional protein which in-
teracts with p53 and BCL2 antagonist/killer (BAK 34) to
increase the chromosomal instability and cellular resist-
ance to apoptosis [17]. E7 protein interacts with retino-
blastoma (RB) resulting in E2F release, a transcription
factor which promotes cell proliferation. E7 up-regulates
S-phase genes, cyclin A, and cyclin E but,contrarily,
inhibits the cyclin-dependent kinase inhibitors such as the
cyclin-dependent kinase inhibitor (WAF 1), known as p21,
and Kinesin-like protein (KIP 1), known as p27 [16, 18].
Other equally important cellular factors, which interact
with HPV proteins, are breast and ovarian cancer suscepti-
bility gene-1 (BRCA1) and BRCA2. These genes are known
for their tumor suppressor products, which prevent tumor
development by repairing DNA damages. These proteins
activate c-Jun N-terminal kinase/stress-activated pro-
tein kinase (JNK/ SAPK) that eventually lead to apop-
tosis [19–21]. E7 and E6 interact with BRCA1 and
antagonize several functions of BRCA1 [22].
Other factors such as inflammation have been shown
to be involved in breast cancer progression. Chronic in-
flammation, which can be caused by persistent virus in-
fections, is mediated by different cytokines and reactive
oxygen nitrogen species (RONS). This chronic situation
could suppress the antitumor immunity, promote metas-
tasis development, and contribute to tumor progression
[23–25]. Moreover, inflammation could enhance tumor
progression which results in tissue remodeling, induc-
tion of the growth factors and angiogenesis [6]. Different
cytokines such as transforming growth factors like beta
(TGF-β), interleukin 1 (IL-1), IL-6, and IL-17 could
stimulate breast cancer cell proliferation and/or invasion
[26]. IL-6 is one of the inflammatory cytokines involved
in tumor growth by evoking anti-apoptotic response and
stimulating tumor development [27]. TGF-β is a multi-
functional cytokine involved in regulating many
processes including differentiation, proliferation, and
apoptosis of cancer cells. This cytokine seems to be the
most extensively studied factor in breast cancer molecu-
lar studies [24]. During the inflammation, increased
levels of IL-1 could induce breast cancer progression via
angiogenesis, cell proliferation, and inhibition of apop-
tosis [28, 29]. Tumor necrosis factor α (TNF-α), is
another inflammatory cytokine expressed in high
amounts and involved in breast cancer [24]. TNF-α, IL-6
and TGF-β promote the production of IL-17 which affects
chronic inflammatory responses and thus tumor develop-
ment [25]. NF-κB (nuclear factor kappa-light-chain-enhan-
cer of activated B cells) is a protein which plays a critical
role in regulating the immune response against infections.
This feature seems to be the main linker between tumor
development and inflammation [30]. Several studies have
shown that NF-κB has a direct association with tumor initi-
ation and cancer progression [31]. High levels of RONS in
cancer tissue can significantly promote tumor development
and metastasis [32, 33]. Chronic infection and inflamma-
tion are the cause of 20–25% of all human cancers [34].
Therefore, investigating the role of infection and inflamma-
tion in tumor initiation and development has been
attracted intensive scientific interests in the fields of oncol-
ogy and virology.
In the present case-control study, we aimed to deter-
mine the presence of HPV in breast cancer tissues and
to evaluate the possible association between HPV infec-
tion and breast cancer development.
Methods
Samples, methodology, and ethical standards
This multi-central case control study was performed
between January 2015 and March 2016 in the Kashani
Hospital (Shahrekord, Iran) and Rasul-e Akram Hospital
(Tehran, Iran). According to the inclusion and exclusion
criteria, 72 breast specimens were collected, and all tissue
samples were immediately snap frozen in liquid nitrogen
and stored at − 80 °C. Inclusion criteria were defined as;
women with approved histopathological (biopsy)
evidence(s) of breast cancer, accessibility of fresh samples,
native patients of Shahrekord and Tehran cities. Also,
different parameters such as past or current medical
history of chemotherapy and/or radiotherapy, being preg-
nant, biologic anti-cancer therapies, and systemic inflam-
matory disease such as rheumatoid arthritis were defined
as exclusion criteria. No limitations in age, type of breast
cancer, and tumor size or stage were considered for the
patients. In addition, 31 normal breast tissue samples, ob-
tained from breast reduction surgeries with normal histo-
pathology results, were also examined as healthy controls
(from both hospitals). All the controls were healthy
women with no history of estrogen therapies, oral contra-
ceptive consumption, cervical cancer, and smoking. For all
the cases a carful breast examination was performed by an
experienced surgeon. All the histopathology results were
re-examined by two well experienced pathologists (double
checking by M. Mogani and M. Khosravi) to certainly
confirm the diagnosis. The stage of cancer, based on TNM
system, was provided by consulting an expert cancer team
consisting of an oncologist, a radiologist and a cancer sur-
geon. Tumor samples were classified histologically based
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on the World Health Organization (WHO) criteria [35].
Five paraffin-embedded pathologically proved cervical
cancer samples were used as positive controls. All the par-
ticipants signed a copy of consent form freely after verbal
explanation of the aims and methods of this study accord-
ing to their level of knowledge.
HPV detection, genotyping and physical status
The DNA extraction was performed using “QIAamp
Tissue Kit” according to the manufacturer’s instructions
(QIAGEN, Hilden, Germany). A polymerase chain reac-
tion (PCR)-based detection assay was employed to iden-
tify HPV, using primers for L1 and E7 genes [1].
Genotypes of HPV positive samples were determined by
INNO-LiPA HPV Genotyping v2 test (Innogenetics,
Ghent, Belgium) in strict accordance with the manufac-
turer’s instructions. For this test, distilled water and par-
affin sections without tissue were used as negative
controls for PCR and DNA extraction, respectively.
Moreover, isolated genotypes (6, 11, 15, 16, 18, and 33)
of cervical cancer samples, in CIN3 and cervical cancer
model, were used as positive controls for amplification.
The serial dilutions of the full-length HPV genome was
prepared to provide the standard control for copy num-
ber of E2 and E6 genes [36].
Expression level of cellular and viral factors
E6
Total RNA was extracted and purified from the tissue by
using RNEasy Mini kit (QIAGEN, Hilden, Germany).
Real-time PCR (RT-PCR) reactions were conducted with
one step RT-PCR® kits (QIAGEN, Hilden, Germany)
according to the manufacturer’s instructions. The
used primers for amplifying the gene sequence for E6
were [37]:
Forward 5′-GCAATGTTTCAGGACCCACA-3′
Reverse 5′-ACAGCATATGGATTCCCATCTC-3′.
p53
The level of p53 was assessedusing enzyme-linked im-
munosorbent assay (ELISA) using Abcam’s p53 Simple
Step ELISA® Kit (Abcam, Cambridge, MA, USA) accord-
ing to the manufacturer’s instructions.
E7
For cDNA synthesis, 1 microgram of extracted total
RNA was reverse transcribed using the QuantiNova Re-
verse Transcription® Kit (QIAGEN, Hilden, Germany).
The used primers and probe in E7 gene amplification
were [38]:
Forward primer: 5’-AAGTGTGACTCTACGCTTCGGTT-3’
Reverse primer: 5’-GCCCATTAACAGGTCTTCCAAA-3’
Probe: FAM-TGCGTACAAAGCACACACGTAGAC
ATTCGTA-BHQ
RB
The expression level of RB gene was determined by Hu-
man Retinoblastoma ELISA® kit (Sigma-Aldrich, Saint
Louis, USA) according to the manufacture’s protocol.
E2
Quantitative SYBR green TaqMan Universal PCR Master
Mix® (QIAGEN, Germany) was used to monitor expres-
sion levels of E2 genes. The used primers in E2 gene
amplification were [39]:
Forward primer: 5’-CTACGAATTCATGGAGACT
CTTTGCCAACG-3′
Reverse primer: 5’-GATAGAATTCTCATATAGA
CATAAATCCAG-3′
BRCA1 and BRCA2
The expression level of BRCA1 and BRCA2 were mea-
sured by BRCA1 and BRCA2 ELISA Kits (Human)
(MyBioSource, Inc. CA, USA) according to the manufac-
ture’s protocol.
Cytokines and NF-kB evaluation
The levels of IL-1, IL-6, IL-17 and NF-kB were measured
using Human IL-6 ELISA® Kit, Human IL-1 beta ELISA®
Kit, Human IL-17 ELISA® Kit, and NFkB p65 Transcrip-
tion Factor Assay® Kit (Abcam, Cambridge, MA, USA),
respectively, according to the manufacturer’s instruc-
tions. Moreover, the amount of TGF-β and TNF-α were
measured by Human TGF-beta 1 Quantikine ELISA® Kit
(Minneapolis, MN, USA) and Human TNF Alpha
PicoKine™ ELISA Kit (Boster Biological Technology,
Pleasanton CA, USA), respectively, according to the
manufacturer’s instructions.
Reactive oxygen species and reactive nitrogen species
The RONS level was assessed by OxiSelect™ Intracellular
ROS/RNS Assay kit (Cell Biolabs, Inc., San Diego, CA),
following the protocol.
Statistical methods
Normality test was performed using Kolmogorov–Smir-
nov test for continuous variables. The two-independent
samples t-test (Mann-Whitney non-parametric test) was
conducted to compare the central tendency (e.g. mean
for normal and median for non-normal gene expression)
of gene expressions in such two groups. Correlation ana-
lysis was also carried outby Eta-squared coefficient. To
identify the linear dependencies between two sets of the
variables, the Canonical Correlation Analysis (CCA) was
applied. Generalized linear model (logistic regression)
was used to recognize the association between the pres-
ence of HPV and breast cancer. Moreover, for this test
odds ratio (OR) as the effect size with 95% confidence
intervals (95% CI) was measured. False discovery rate
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was corrected by Benjamini-Hochberg approach for
multiple comparisons. All data were finally analyzed
using IBM SPSS version 21.0 (SPSS, Chicago, IL, USA)
and GraphPad Prism version 6 (La Jolla, CA, USA). Any
P-value less than 0.05 were considered statistically
significant.
Results
In this study, 72 female breast cancer cases, including 9
(12.5%), 20 (27.8%), 32 (44.4%), 3 (4.2%), and 8 (11.1%)
patients with medullary carcinoma, invasive lobular car-
cinoma, invasive and in-situ ductal carcinoma, mucinous
carcinoma, and tubular carcinoma were examined. The
average age of the patients was 48.86 ± 10.95 years, ran-
ging from 30 to 81 and for the controls it was 48.97 ±
9.22 years old (ranged from 35 to 72), which was similar
to the age of the patients (P = 0.76) (Table 1).
HPV DNA was detected in 35 out of 72 patients
(48.6%) and 5 out of 31 healthy controls (16.1%). The
presence of HPV infection in the breast cancer control
was found to be statistically significant (P = 0.003). The
odds of breast cancer incidence in the HPV positive
group was 4.92 (95% C. I: 1.699–14.238), which was sig-
nificantly more than HPV negative group. In the breast
cancer group, five different genotypes were detected,
namely, 18 (N = 16, 22.2%), 16 (N = 13, 18.1%), 33 (N = 4,
5.6%), 6 (N = 1, 1.4%), and 11 (N = 3, 4.2%), while, in the
healthy control group only two genotypes was observed;
18 (N = 3, 9.7%) and 16 (N = 2, 6.5%) (Table 1). The
papillomavirus E2 gene expression was absence in 30
cases of breast cancer group (86%, P = 0.006), there-
fore the genome of HPV E2 negative group was in an
integrated form. However, the E2/E6 ratio was lower
than 1 which indicates that HPV was in both epi-
somal and integrated forms known as mixed form (N
= 5, 14%). Also, the E2/E6 ratio in positive control
group (5 cervical cancer samples), showed that only
20% (ration 1) was integrated and the other were epi-
somal form, 80% (ratio 4) (E2/E6 ≥ 1(. The E2/E6 ra-
tios and viral physical status in different cancer types
and stages are compiled in Table 2. HPV DNA was
detected in 16 patients (45.7%) with ductal carcinoma
(highest ratio), and no patients (0%) with mucinous
carcinoma (lowest ratio) was observed. Moreover, no
significant association between histological types of
breast cancer and HPV infection was detected (P =
0.32). A significant difference was found in the inci-
dence of HPV infection between cases and controls
(P = 0.003). Also, the association of HPV genotypes
and occurrence of breast cancer was statistically sig-
nificant (P = 0.037). The frequency distribution of
breast cancer stages and genotypes between HPV pos-
itives and HPV negatives controls were statistically
different and the association of HPV with stages of
breast cancer and genotypes was also significant
(P = 0.045 and P < 0.001, respectively) (Table 3).
Table 1 Comparison of participants’ characteristics between cases and controls
Characteristics Breast cancer group (N = 72) Healthy controls (N = 36) P-value OR (95% CI)
Age (Year) 48.86 ± 10.95 48.97 ± 9.22 0.76 –
HPV Presence 35 (48.6%) 5 (16.1%) 0.003 4.92 (1.70–14.24)
Absence 37 (51.4%) 26 (83.9%) –
Stage of Cancer Ia, Ib 2 (2.7%), 9 (12.5%) – – –
IIa, IIb 20 (27.8%), 19 (26.3%) – – –
IIIa, IIIb, 5 (6.9%), 9 (12.5%), – – –
IIIc 6 (8.3%)
IV 2 (2.7%) – – –
Type of Cancer Ductal 32 (44.4%) – – –
Lobular 20 (27.8%) – – –
Medullary 9 (12.5%) – – –
Tubular 8 (11.1%) – – –
Mucinous 3 (4.2%) – – –
Genotype Negative (−) 35 (48.6%) 26 (83.9%) 0.037 –
HPV-18 16 (22.2%) 3 (9.7%)
HPV-16 13 (18.1%) 2 (6.5%)
HPV-33 4 (5.6%) –
HPV-11 3 (4.2%) –
HPV-6 1 (1.4%) –
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The expression levels of p53 and RB was found to be re-
duced in HPV-positive breast cancer group compared to
HPV-negative breast cancer and normal healthy controls
(P < 0.001, P < 0.001, P = 0.033, respectively) (Table 4). In
addition, there was a direct association between the de-
creased expression of the tumor suppressor genes (p53,
RB, BRCA1 and BRCA2) and the progression stage of
breast cancer. The results showed a significant
negative association between expression of E6 and
p53 (P = − 0.743, P < 0.001), and similar association
between the expression level of E7 and RB (P = − 0.805,
P < 0.001) was detected. According to CCA result, stan-
dardized canonical correlation coefficient between the ex-
pressions of inflammatory factors and viral proteins (E2,
E6 and E7) were statistically significant (P = 0.692 and
P = 0.009). The expression levels of different inflammatory
factors including IL-1, IL-6, IL-17, TGF-β, TNF-α, NF-κB,
and RONS were statistically higher in HPV- positive
Table 2 Physical status of HPV genome in cases and controls
Cases (%) Controls (%) Total number P-value
Integrated 30/35 (86%) 1/5 (20%) 31/40 (77.5%) 0.006
Stages: Types:
Ductal (n = 11)
I (n = 3) Lobular (n = 4)
II (n = 3) Medullary(n = 6)
III (n = 9) Tubular (n = 5)
IV (n = 15) Mucinous (n = 4)
Episomal – 4/5 (80%) 4/40 (10%) NA
Mixed 5/35 (14%) – 5/40 (12.5%) NA
Stages: Types:
I (n = 3) Ductal (n = 3)
II (n = 2) Lobular (n = 0)
III (n = 0) Medullary(n = 1)
IV (n = 0) Tubular (n = 1)
Mucinous (n = 0)
NA: Not applicable
Table 3 Comparison of participants’ characteristics between HPV positive and HPV negative groups in breast cancer cases
Characteristics HPV+ HPV- P-value OR (95% CI)
Age (Year) 48.00 ± 11.11 49.46 ± 9.99 0.49 –
Stage of Cancer I 4 (11.5%) 7 (18.9%) Ref. Ref.
II 15 (42.8%) 24 (64.9%) 0.89 1.09 (0.27–4.38)
III 14 (40%) 6 (16.2%) 0.076 4.08 (0.86–19.37)
IV 2 (5.7%) 0 0.22 NA
Type of Cancer Tubular 5 (14.3%) 3 (8.1%) Ref. Ref.
Ductal 16 (45.7%) 16 (43.2%) 0.53 0.60 (0.12–2.94)
Medullary 4 (11.4%) 5 (13.5%) 0.46 0.48 (0.06–3.35)
Lobular 10 (28.6%) 10 (27%) 0.55 0.60 (0.11–3.21)
Mucinous 0 3 (8.1%) 0.15 NA
Genotype Negative (−) 0 61 (96.8%) < 0.001 NA
HPV-18 18 (45%) 1 (1.6%) Ref. Ref.
HPV-16 15 (37.5%) 0 0.58 NA
HPV-33 4 (10%) 0 0.85 NA
HPV-11 2 (5%) 1 (1.6%) 0.17 0.11 (0.005–2.55)
HPV-6 1 (2.5%) 0 0.44 NA
Ref: reference level for the categorical variable, NA: not applicable
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breast cancer patients than control samples and
HPV-negative breast cancer patients. More details are pre-
sented in the Tables 5, 6 and Fig. 1.
Discussion
Breast cancer incidence and mortality rates are increas-
ing markedly worldwide. This highlights the importance
of identifying new RFs that are related to breast cancer
development, in order to prevent or treat the disease
[40]. Several factors are involved in initiation and devel-
opment of cancer, among which are critically important
biological carcinogens such as viral infections [41]. Viral
infections have been shown to be involved in approxi-
mately 18–20% of cancers [40]. For example, HPV can
induce inflammation due to some of its features includ-
ing production of oncogenic proteins. This makes HPV
a strong suspect for initiation and development of breast
cancer [42].
In this study, among 72 evaluated samples, HPV DNA
was found in 48.6% (n = 35) of breast cancer samples.
Several investigations have reported detecting HPV in
breast cancer patients and its prevalence with a vast
range from 4 to 86% [43]. A recent evaluation conducted
by Sigaroodi et al. (2012, Iran) has shown a high fre-
quency of HPV DNA in breast cancer patients (25.9%)
in contrast to the women with non-cancerous condition
(2.4%). According to their results, the HPV genotypes 16
and 18 with the accumulated prevalence of 53.34% in
breast cancer patients were the most predominant. This
study also showed that breast cancer in Iranian women
was associated with HPV infection (OR 14.247, 95% CI
1.558–130.284; P = 0.019) [14]. Another investigation
which performed by Salman et al. (2017, UK) reported
the presence of HPV genome (42%) in breast cancer pa-
tients, concluding that high expression level of E6 and
E7 and their interactions with cellular factors can led to
breast tumor development [40]. These results are con-
sistent with our results and also with earlier studies on
cervical cancer [44, 45]. Other investigations have re-
ported different prevalence of HPV in breast cancer pa-
tients as follows; 41.6% (2015, Venezuela), 40% (2013,
Mexico) and 21% (2008, Japan) [36, 46, 47]. Our result
and other studies have been compared in Table 7. It is
noteworthy that despite using viral DNA detection
method to show the presence of the virus, this does not
demonstrate the active infection. [40]. Several studies
have shown the expression of the HPV proteins in breast
tissue is a reliable marker to detect the active infection.
For instance, it has been demonstrated that the expres-
sion level of E7 in breast cancer tissue was higher than
healthy controls and patients with early stages of cancer
[40]. Therefore, we assessed the expression level of E6
and E7 to evaluate the viral activity.
HPV 16 and 18 genotypes are considered as two of the
most common virus genotypes that can be found in can-
cers worldwide [36, 47]. Other types of HPV including 6,
11, 33, 35, 39, 45, 51 and 59 have been also detected in
breast cancers patients [40, 46, 48]. For the first time,
Yingyan Yu et al. (2000, China) reported the detecting
HPV-33 in 43.8% of their evaluated patients with breast
Table 4 Comparison of RB and p53 expression levels between patients with breast cancer/ HPV positive groups and control
samples/ HPV negative groups
Expression level Breast Cancer
(N = 72)
Control
(N = 31)
Fold Change Adjusted
P-value
HPV positive
(N = 40)
HPV negative
(N = 63)
Fold Change Adjusted
P-value
RB 7.89 ± 5.74 10.65 ± 6.39 0.74 0.033 3.25 ± 3.29 12.19 ± 4.67 0.27 < 0.001
P53 9.81 ± 7.51 17.19 ± 6.02 0.57 0.001 5.30 ± 4.46 16.30 ± 6.41 0.33 < 0.001
Table 5 Comparison expressions level of TGF-β, IL-17, IL-6, IL-1, TNF-α, NF-κB, ROS, RNS, BRCA1 and BRCA2 in breast cancer, control
samples, positive HPV, and negative HPV samples
Expression level Breast Cancer
(N = 72)
Control
(N = 31)
Fold Change Adjusted
P-value*
HPV positive
(N = 40)
HPV negative
(N = 63)
Fold
Change
Adjusted
P-value*
TGF-β 12.40 ± 9.11 5.29 ± 3.68 2.34 0.0013 18.65 ± 7.53 4.94 ± 3.06 3.75 0.001
IL-17 12.61 ± 9.46 4.97 ± 4.29 2.54 0.0013 20.05 ± 6.28 4.13 ± 3.33 4.85 0.001
IL-6 9.32 ± 7.27 3.97 ± 3.29 2.35 0.0013 14.30 ± 5.58 3.52 ± 3.22 4.06 0.001
IL-1 8.90 ± 6.21 6.10 ± 4.48 1.46 0.0103 14.65 ± 5.06 3.87 ± 2.30 3.78 0.001
TNF-α 9.40 ± 7.56 4.77 ± 3.28 1.97 0.0013 15.83 ± 6.33 3.05 ± 3.01 5.19 0.001
NF-κB 9.26 ± 7.67 5.48 ± 4.91 1.69 0.0290 14.75 ± 5.97 3.92 ± 3.51 3.76 0.001
ROS 10.08 ± 8.87 3.35 ± 3.06 3.01 0.0013 16.38 ± 7.29 2.78 ± 2.47 5.89 < 0.001
RNS 11.32 ± 9.84 3.94 ± 2.88 2.87 0.0013 17.82 ± 8.82 3.56 ± 2.83 5.01 < 0.001
BRCA1 9.58 ± 5.35 14.45 ± 4.58 0.66 0.0013 8.32 ± 4.43 12.77 ± 5.58 0.65 < 0.001
BRCA2 7.23 ± 3.84 12.66 ± 4.03 0.57 0.0013 5.15 ± 1.92 11.22 ± 3.79 0.46 < 0.001
* FDR correction for multiple comparisons by Benjamini-Hochberg method
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cancer. However, they did not report the presence of
HPV-16 and HPV-18 DNA in their cases [48]. In the
current study, we reported the prevalence of HPV-33 to
be 5.6% in breast cancer samples but not in any of
healthy controls. There could be several hypotheses ad-
dressing this difference, prevalence and genotypes distri-
bution of HPV, including geographical, sample size,
sampling, and methodological differences [36, 49].
Among all the mentioned reasons, it seems that the
main reason could be the difference in the geographical
areas which may cause variety in the prevalence of HPV
type distribution. Another important factor is the sensi-
tivity of methods used to detect viral genome. For in-
stance, the use of different primer sets may result in
highest sensitivity and specificity. In the current study,
two sets of primers were used for L1 and E6/E7, since
L1 gene is frequently lost during HPV integration into
the host genome [50]. Although different methods such
as in situ hybridization (ISH) could be used for HPV
DNA detection, but this method may not detect HPV
DNA in some samples. Therefore, it has been suggested
that the PCR can be more sensitive than ISH [49]. A
study has been conducted to compare the sensitivity of
PCR and ISH methods for the detection of HPV in pa-
tients with breast cancer. This investigation was consid-
ered since they used PCR method to show the presence
of HPV DNA in 46% of breast cancer cases, while using
ISH resulted in only one positive case [51]. Our results
showed that in the group of HPV DNA positive patients,
the ductal carcinoma was more frequent than other
types of cancer (N = 16, 45.7%). It was also accompanied
with the lower incidence of mucinous carcinoma (0%).
Also, we showed that the highest HPV incidence was
similar to the recent study investigating on the role of
HPV in breast carcinogenesis in the UK. In contrast, the
prevalence of HPVs DNA in lobular carcinoma was
found to be the lowest [40].
The E2/E6 ratio was used to determine the physical
status of HPV genome. When the ratio is equal to zero,
larger than zero and smaller, equal to or higher than 1,
HPV genome is integrated, made up from both episomal
and integrated forms and episomal form, respectively
Table 6 Associations between expression level of TGF-β, IL-17, IL-6, IL-1, TNF-α, NF-κB, ROS, RNS, BRCA1 and BRCA2 with breast cancer
and presence of HPV
Expression
level
Breast Cancer Presence of HPV
Correlation Coefficient Adjusted P-value* Correlation Coefficient Adjusted P-value*
TGF-β 0.608 0.0016 0.877 < 0.001
IL-17 0.618 0.0087 0.953 < 0.001
IL-6 0.464 0.0016 0.959 < 0.001
IL-1 0.497 0.0410 0.949 < 0.001
TNF-α 0.602 0.0071 0.971 < 0.001
NF-κB 0.418 0.0155 0.953 < 0.001
ROS 0.613 < 0.001 0.958 < 0.001
RNS 0.633 < 0.001 0.956 < 0.001
BRCA1 0.831 < 0.001 0.797 < 0.001
BRCA2 0.736 < 0.001 0.952 < 0.001
* FDR correction for multiple comparisons by Benjamini-Hochberg method. Eta-squared considered as an effect size of correlation
Fig. 1 Comparison of inflammation factors, BRCA1 and BRCA2 expression level: (a) in breast cancer with control, (b) in HPV positive with HPV
negative samples
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[36, 52]. Previous studies have shown that physical status
of HPV DNA in cervical cancer is considered as a
marker of tumor development [52]. Khan et al. detected
HPV DNA in 21% of evaluated breast cancer samples.
They demonstrated that all the HPV genome was con-
sidered integrated into the host genome except for one
case which was a mixed form [36]. Islam and colleagues
reported a prevalence of 63.9% for HPV in patients with
breast cancer, demonestirating that 87.5% of their pa-
tients with positive HPV had integrated genome and
4.2% were in episomal form [53]. In the present study,
according to the E2/E6 ratio, 30 (86%, P = 0.006) and 5
(14%) of HPV genomes were integrated and mixed form,
respectively. Our results demonstrated that E2/E6 ratio
was significantly different in the tumor types and stages.
Most integration and mixed form were detected in
ductal form of tumor and stages III and IV. Such high
rate of integration is accompanying with tumor develop-
ment because this finally leads to increasing the expres-
sion level of E6 and E7. This issue has already been
proven in Cervical Cancer [40]. One of the limitations in
our study was to use E2/E6 ratio for determination of
physical status of HPV genome while Zhang et al. have
demonstrated that E2/E6 or E2/E7 is less sensitive and
predictive than E2/E6E7 for determination of physical
status of HPV genome in cervical cancer [54]. Therefore,
in our study, the percentage of integrated HPV genomes
was probably more than the percentage we reported. On
the other hand, the multiple E1-L1/E6E7 ratio analysis
needs four more PCR reactions than E2/E6E7 ratio ana-
lysis. Further studies is required to estimate the cost-ef-
fectiveness of this modification, which can be considered
as a drawback. [54]. To the best of our knowledge, this is
the first study reporting the physical status of HPV gen-
ome in breast cancer tissue in Middle East.
There are numerous distinct stages from the beginning
of viral infection to the tumor development. For example,
the progression of cervical tumors in patients infected by
HPV are including these models: (1) HPV infection CIN 1,
2; (2) persistent HPV-infection, CIN 1, 2; (3) CIN 3; (4)
cervical cancer. These stages are affected by different co-
factors [9, 55]. The role of HPV in initiation and develop-
ment of breast cancer can be discussed from two aspects:
(1) Direct role; interactions of viral proteins with key regu-
lator proteins of the cell, (2) Indirect role; induction of
inflammation.
Through targeting p53 and RB, oncoproteins of HPV
such as E6 and E7 could disrupt the cell cycle, initiate
malignant transformation and finally lead to tumor de-
velopment [44]. This is inevitable since p53 and RB play
crucial roles in controlling cell cycle and genome repair,
and therefore interference and degradation of these pro-
teins may lead to uncontrolled cellular proliferation and
finally cancer. Herein, it was demonstrated that compared
to controls, the expression levels of p53 and RB in cancer
samples were decreased significantly (P = 0.001 and P =
0.033 respectively). Also, the expression levels of p53 and
RB were compared between HPV positive and HPV nega-
tive patients diagnosed with breast cancer and it was
showed that these levels were significantly reduced in
HPV-positives breast cancer patients compared to
HPV-negatives breast cancer patients (both P < 0.001).
In the breast, as well as all other tissues, the BRCA1
and BRCA2 are expressed and involved in repair process
of damaged DNA and any reduction or disruption of
these two proteins could lead to cancer [56]. It has been
shown that E6 and E7 proteins are able to interact with
the BRCA1 (as the antagonists) and alter its activity.
Moreover, BRCA1 interacts with RB and p53. This inter-
action is required for the RB functioning in G1 check-
point of cell cycle. Also, BRCA1 acts as a co-activator of
p53-mediated transcription [22]. Thus, HPV proteins
(E6 and E7), may influence RB and p53 functions with
indirect interference through BRCA1 pathway. In
addition, we demonstrated that the expression levels of
BRCA1 and BRCA2 were reduced in breast cancer tissue
in comparison to the healthy controls (for both P =
0.0013). Moreover, in HPV-positive breast cancer pa-
tients BRCA1 and BRCA2 were decreased (both P <
0.001) compared to the HPV-negative group., suggesting
Table 7 Evaluation of differences in prevalence of HPV infected breast cancer patients among different studies
Study Year/Country HPV+ patients HPV+ controls Most prevalent HPV
Current study 2017/Iran 48.6% 16.1% HPV-18 (22.2%)
Islam et al. 2017/India 63.9% 9.5% HPV-16 (69%)
Salman et al. 2017/UK 42% 17% HPV-39 (20%)
Fernandes et al. 2015/ Venezuela 41.6% NA HPV-51 (30.7%)
Herrera-Goepfert et al. 2013/Mexico 40% NA HPV-16 (87.5%)
Sigaroodi et al. 2012/Iran 25.9% 2.4% HPV-16 and 18 (both 25%)
Khan et al. 2008/Japan 21% NA HPV-16 (92%)
Yu et al. 2000/China 43.8% NA HPV-33 (43.8%)
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that the role of HPV in breast cancers could be accom-
plished through interacting with these proteins.
Previous studies indicated that onco-viruses can be
considered as a cause some types of cancers, but these
infections seem to be just a prerequisite and viral infec-
tions can only provide some of the conditions which is
necessary for carcinogenesis. Although, high-risk HPV
types can lead to transform the human keratinocytes
into cancer cells in vitro, without any additional factors
[57], other co-factors such as chronic inflammation,
environmental mutagens, and immunosuppression are
required to carcinogenesis [58, 59]. Several epidemio-
logical and clinical investigations have demonstrated that
certain pathogens leading to persistent infection(s) are
strongly correlated with cancer prevalence [60]. Persist-
ent viral infections usually cause chronic inflammation
through different factors such as induction of RONS
production and producing mitogenic and angiogenic fac-
tors [25, 61]. Inflammation could be considered as a
double-edged sword; in the initial steps it is crucial for
provoking anti-tumor responses by the immune system
and after that, it favors tumor development by triggering
angiogenesis [23]. Recent investigations indicated that
the inflammation is the major hallmark for tumor pro-
gression [60, 62]. Among the inflammatory cytokines,
IL-1, TGF-β, and IL-6 are responsible for cancer cells
proliferation and invasion through activation of NF-κB.
TNF-α, another inflammatory cytokine, is responsible in
the main pathways of tumor inflammation. Moreover, it
has been shown that TNF-α--NF-κB axis is related to the
invasiveness and malignant behavior of breast cancer cells.
TNF- α, IL-1, TGF-β, and IL-6 are able to induce the ex-
pression of many angiogenic growth factors in tumor such
as vascular endothelial growth factor (VEGF) [24]. Also,
IL-17 is related to the cancer cell survival and invasion as
well as regulation of angiogenesis [63]. The present study
clearly showed that the expression of inflammatory factors
including IL-1, IL-6, IL-17, TNF-α, TGF-β, NF-κB and
RONS in HPV-positive breast cancer patients were higher
than HPV-negative breast cancer patients and healthy
controls (Fig. 1 and Table 5). This indicated a significant
role of inflammation in cancer induction among HPV in-
fected patients with breast cancer. The increased inflam-
matory status caused by HPV may increase tumor
development and tumor cells’ survival as well as angiogen-
esis [22], and consequently this lead to cancer cells prolif-
eration and tumor metastasis [23]. Taken together, it
seems that the detected inflammation in these patients
may be related to viral infection, persistent infection, and
its proteins. Despite all the results of this study, the
role of HPV in breast cancers is still questionable. To
the best of our knowledge, this is the first study
reporting the association between inflammation and
HPV in breast cancer patients.
Conclusion
In the current study, HPV genome was detected in
48.6% of breast cancer samples among which most
(82.8%) were at stage II and III. Being infected with HPV
as a risk factor could directly or indirectly interfere with
certain cellular mechanisms which lead to tumorigenesis
and cancer development. We demonstrated that HPV is
associated with breast cancer development, although the
role of HPV in breast cancers is still questionable and
further research is required to investigate, in more detail,
the role of HPV infection in breast cancer.
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